News from santaris pharma a/s A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 10, 2014, 08:00 ET Santaris Pharma A/S announce agreement with GlaxoSmithKline (GSK) to develop RNA-targeted medicines

Santaris Pharma A/S has announced today that they have signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK...


Jan 08, 2014, 08:00 ET Santaris Pharma A/S Announces Appointment of J. Donald deBethizy as President and Chief Executive Officer

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Jan 08, 2014, 08:00 ET Isarna Therapeutics and Santaris Pharma Announce License Agreement for the Development of Next Generation Oligonucleotides to Treat TGF-Beta-Mediated Diseases

Santaris Pharma A/S and BetaIsarna Therapeutics GmbH announced today that they have signed an agreement whereby Isarna gains access to Santaris'...


Oct 28, 2013, 08:00 ET Santaris Pharma A/S resumes full ownership of cancer programs licensed to Enzon Pharmaceutical Inc.

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Aug 23, 2013, 02:00 ET Shire and Santaris extend their strategic alliance to discover and develop LNA-drugs in the rare genetic disease field

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Jul 08, 2013, 08:00 ET RaNA Therapeutics, Inc. and Santaris Pharma A/S announce agreement to develop RNA-targeted medicines that selectively activate protein expression

Santaris Pharma A/S and RaNA Therapeutics, Inc. announced today that they have signed an agreement whereby RaNA gains access to Santaris' Locked...


Apr 18, 2013, 08:00 ET EPO appeal board decides in favor of the Wengel LNA patent

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Apr 16, 2013, 02:00 ET Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted medicines

Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs,...


Apr 05, 2013, 08:00 ET USPTO issues Inter Partes Reexamination Certificate of key LNA patent

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Mar 28, 2013, 06:34 ET Forskning udgivet i New England Journal of Medicine påviser markant og langvarig antiviral aktivitet mod HCV for Santaris Pharma A/S' Miravirsen, det første MicroRNA-rettede lægemiddel til at indgå i kliniske forsøg

Santaris Pharma A/S, en klinisk-faset, biofarmaceutisk virksomhed, der fokuserer på forskningsresultater fra og udvikling af RNA-rettede...


Mar 27, 2013, 05:00 ET Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S' Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Jan 08, 2013, 08:00 ET Santaris Pharma A/S and miRagen Therapeutics Inc. expand worldwide strategic alliance to discover and develop LNA-drugs against disease causing microRNAs

Santaris Pharma A/S and miRagen Therapeutics, Inc. today announced that they have expanded their existing partnership in the field of microRNA...


Jan 07, 2013, 08:00 ET USPTO Grants Santaris' Request for Inter-Partes Reexamination of Patent licensed to Regulus

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Sep 24, 2012, 08:00 ET Court Focuses Patent Suit on Santaris's Safe Harbor Defense

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Apr 20, 2012, 04:02 ET Santaris Pharma A/S præsenterer de endelige Fase 2a-undersøgelsesresultater for miravirsen, der viser dosisafhængig, langtidsvirkende antiviral aktivitet hos patienter med Hepatitis C

-- Data vil blive fremlagt i en mundtlig fremstilling på EASL's årlige generalforsamling – - Miravirsen er et pan-genotype HCV antiviralt stof rettet ...


Apr 19, 2012, 05:00 ET Santaris Pharma A/S presents final Phase 2a study results for miravirsen showing dose-dependent, prolonged antiviral activity in Hepatitis C patients

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present...


Nov 30, 2011, 07:15 ET United States Patent and Trademark Office Upholds Key Santaris Pharma A/S LNA Patents in Two Re-Examination Cases Brought by Isis Pharmaceuticals

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced...


Nov 05, 2011, 09:00 ET Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, presents new data ...


Nov 05, 2011, 09:00 ET Santaris Pharma A/S' Phase 2a forsøg med miravirsen i patienter inficeret med Hepatitis C viser efter fire ugers behandling en dosis-afhængig, langtidsvirkende virus reduktion med 2-3 logs i HCV RNA

- Nye Phase 2a kliniske data præsenteres på AASLD - - Miravirsen blev indgivet i fire uger som eneste behandlingsform og viste en signifikant...


Oct 03, 2011, 07:15 ET Santaris Pharma A/S to Report New Clinical Data From Miravirsen Phase 2a Study to Treat Hepatitis C in Late-Breaking Oral Presentation at the AASLD 2011 Annual Meeting

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies,...


Sep 07, 2011, 07:15 ET Santaris Pharma A/S Showcases microRNA and mRNA Research Advancements Utilizing its Proprietary Locked Nucleic Acid Technology at Oligonucleotide Therapeutics Society Meeting

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies,...


Sep 07, 2011, 01:15 ET Santaris Pharma A/S præsenterer microRNA og mRNA forskningsresultater baseret på virksomhedens Locked Nucleic Acid teknologi på årets Oligonucleotide Therapeutics Society konference

Santaris Pharma A/S præsenterer fremskridt i virksomhedens udvikling af miravirsen, et microRNA-rettet lægemiddel, som inhiberer miR-122....


May 11, 2011, 07:15 ET Santaris Pharma A/S Advances a Second Drug From Its Cardiometabolic Program, SPC4955, Inhibiting apoB, into Phase 1 Clinical Trials for the Treatment of High Cholesterol

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies,...


May 11, 2011, 07:15 ET Santaris Pharma A/S indleder endnu et Fase 1 studie med laegemiddel fra virksomhedens kardiometaboliske program: SPC4955, der inhiberer apoB, til behandling af forhøjet kolesterol

Santaris Pharma A/S, et biofarmaceutisk selskab med fokus på forskning i og udvikling af mRNA og microRNA-rettede laegemidler, offentliggjorde i dag, ...


May 04, 2011, 07:15 ET Santaris Pharma A/S indleder Fase 1 studie med nyt kolesterolsaenkende laegemiddel, SPC5001, som inhiberer det spaendende nye target PCSK9, til behandling af forhøjet kolesterolniveau

Santaris Pharma A/S, Santaris Pharma A/S, et biofarmaceutisk selskab med fokus på forskning i og udvikling af mRNA og microRNA-rettede laegemidler,...